NCT00927589View on ClinicalTrials.gov

A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

59

Participants

Timeline

Start Date

July 31, 2009

Primary Completion Date

February 28, 2013

Study Completion Date

February 28, 2013

Conditions

Solid Cancers

Interventions

DRUG

carboplatin

Intravenous repeating dose

DRUG

docetaxel

Intravenous repeating dose

DRUG

trastuzumab

Intravenous repeating dose

Trial Locations (20)

10461

The Bronx

33136

Miami

37232

Nashville

38120

Memphis

59101

Billings

75230

Dallas

76508

Temple

77024

Houston

77030

Houston

77555

Galveston

78229

San Antonio

85258

Scottsdale

87401

Farmington

90211

Beverly Hills

90603

Whittier

92093

La Jolla

92123

San Diego

95403

Santa Rosa

98101

Seattle

67214-3728

Wichita

Sponsors

Lead Sponsor

Genentech, Inc.

All Listed Sponsors

lead

Genentech, Inc.

INDUSTRY